WO2014188716A1 - 網脈絡膜障害の抑制剤 - Google Patents
網脈絡膜障害の抑制剤 Download PDFInfo
- Publication number
- WO2014188716A1 WO2014188716A1 PCT/JP2014/002667 JP2014002667W WO2014188716A1 WO 2014188716 A1 WO2014188716 A1 WO 2014188716A1 JP 2014002667 W JP2014002667 W JP 2014002667W WO 2014188716 A1 WO2014188716 A1 WO 2014188716A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- retina
- inhibitor
- benzoic acid
- choroidal
- acid
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 32
- 150000002148 esters Chemical class 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 14
- YTFHCXIPDIHOIA-DHZHZOJOSA-N Palovarotene Chemical compound C1=CC=NN1CC=1C=C2C(C)(C)CCC(C)(C)C2=CC=1\C=C\C1=CC=C(C(O)=O)C=C1 YTFHCXIPDIHOIA-DHZHZOJOSA-N 0.000 claims abstract description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 81
- 210000001525 retina Anatomy 0.000 claims description 50
- 239000005711 Benzoic acid Substances 0.000 claims description 43
- 235000010233 benzoic acid Nutrition 0.000 claims description 43
- 231100000241 scar Toxicity 0.000 claims description 25
- 230000008602 contraction Effects 0.000 claims description 23
- -1 2- {3-[(1H-pyrazol-1-yl) methyl] -5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl } Vinyl Chemical group 0.000 claims description 19
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 239000003889 eye drop Substances 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 229940012356 eye drops Drugs 0.000 claims description 7
- 239000003885 eye ointment Substances 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 7
- 229920002554 vinyl polymer Polymers 0.000 claims description 7
- 208000012286 optic choroid disease Diseases 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 abstract description 28
- 210000001519 tissue Anatomy 0.000 abstract description 10
- 102000008186 Collagen Human genes 0.000 abstract description 9
- 108010035532 Collagen Proteins 0.000 abstract description 9
- 229920001436 collagen Polymers 0.000 abstract description 9
- 230000036573 scar formation Effects 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 abstract description 7
- 210000002950 fibroblast Anatomy 0.000 abstract description 4
- 210000004498 neuroglial cell Anatomy 0.000 abstract description 4
- 206010003694 Atrophy Diseases 0.000 abstract 2
- 230000037444 atrophy Effects 0.000 abstract 2
- 210000003583 retinal pigment epithelium Anatomy 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 description 26
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 208000032544 Cicatrix Diseases 0.000 description 8
- 230000037387 scars Effects 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 102000003702 retinoic acid receptors Human genes 0.000 description 7
- 108090000064 retinoic acid receptors Proteins 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 6
- 210000003161 choroid Anatomy 0.000 description 6
- 239000000512 collagen gel Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002207 retinal effect Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 206010064930 age-related macular degeneration Diseases 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- 210000002808 connective tissue Anatomy 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 210000001508 eye Anatomy 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 208000002780 macular degeneration Diseases 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000019426 modified starch Nutrition 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- 208000026726 vitreous disease Diseases 0.000 description 3
- 239000003871 white petrolatum Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- FRDAATYAJDYRNW-UHFFFAOYSA-N 3-methylpentanol-3 Natural products CCC(C)(O)CC FRDAATYAJDYRNW-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010015943 Eye inflammation Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N diethyl carbinol Natural products CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000004503 fine granule Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 239000008011 inorganic excipient Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008012 organic excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 108091008695 photoreceptors Proteins 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 230000004243 retinal function Effects 0.000 description 2
- 239000000790 retinal pigment Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000004382 visual function Effects 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical compound CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical class OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 229940096885 Retinoic acid receptor agonist Drugs 0.000 description 1
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 description 1
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 1
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 210000001775 bruch membrane Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 229920003174 cellulose-based polymer Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 201000004709 chorioretinitis Diseases 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 229950000473 palovarotene Drugs 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 210000003994 retinal ganglion cell Anatomy 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 108091008726 retinoic acid receptors α Proteins 0.000 description 1
- 108091008760 retinoic acid receptors γ Proteins 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- NGHMEZWZOZEZOH-UHFFFAOYSA-N silicic acid;hydrate Chemical compound O.O[Si](O)(O)O NGHMEZWZOZEZOH-UHFFFAOYSA-N 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000003537 structural cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229940071127 thioglycolate Drugs 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J9/00—Feeding-bottles in general
- A61J9/08—Protective covers for bottles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to (E) -4- (2- ⁇ 3-[(1H-pyrazol-1-yl) methyl] -5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene -2-yl ⁇ vinyl) relates to a retina choroid disorder inhibitor containing benzoic acid, an ester thereof or a salt thereof as an active ingredient.
- retinal vitreous diseases such as diabetic retinopathy, retinal detachment, and age-related macular degeneration are expected to continue to increase as a cause of blindness.
- biologics such as anti-VERF intraocular injections
- the prognosis of these previously blinded diseases is being improved.
- the prognosis of the visual function of severe cases such as being left and repeated for a long period of time is not good regardless of the initial cases.
- Even if the retinal reversion is obtained by surgery or the intraocular neovascularization can be eliminated by drugs, if the retinal cells have already undergone irreversible secondary damage, descend.
- Even if the wound heals the eye is an organ that does not make any sense if the photoreceptor function is lost. Therefore, in order to maintain the retinal function normally, it is important how the eye inflammation and the subsequent secondary reaction can be controlled with less damage.
- reticulofibrous fibrous scars are often formed in any tissue on the retina, in the retina, or in the subretinal region, which may impair the photoreceptor function.
- Retinal pigment epithelial cells and collagen which is one of the matrix components, particularly type I collagen, are known as typical cell components constituting reticulofibrous scars, and the retina choroids are formed by the formation and contraction of reticulofibrous scars. Functional failure occurs.
- it is considered effective to suppress the contraction of collagen such as retinal pigment epithelial cells, particularly type I collagen, and to prevent deformation and collapse of the tissue structure against recurrent choroidal disorders.
- RAR retinoic acid receptor
- Methyl-2-naphthalenyl) carbamoyl] benzoic acid as an active ingredient is disclosed as a pharmaceutical for the prevention and / or treatment of diabetic retinopathy or age-related macular degeneration (see, for example, Patent Document 1). Therefore, the contribution of each RAR subtype to retinal function improvement is also unclear.
- RAR is involved in various actions such as proliferation, morphogenesis and differentiation in many cells such as inflammation, immunity and structural cells, and the distribution of RAR subtypes is determined in mammalian tissues and organs. It is confirmed that there is a difference depending on. Since the RAR action also has undesirable effects such as an increase in triglyceride by RAR ⁇ , it is expected that the compound having RAR agonist activity has specificity or selectivity for subtypes, leading to a reduction in the risk of side effects. The In view of the above, there is a need for RAR agonists that have a strong repressor choroidal disorder inhibitory action and have high safety based on subtype selectivity.
- RAR ⁇ selective agonists include (E) -4- (2- ⁇ 3-[(1H-pyrazol-1-yl) methyl] -5,5,8,8-tetramethyl-5,6,7,8 -Tetrahydronaphthalen-2-yl ⁇ vinyl) benzoic acid is useful for emphysema, cancer, and skin diseases (see, for example, Patent Document 2) and useful for neuropathic pain (for example, Patent Document 3) Reference).
- An object of the present invention is to provide a retina choroidal disorder inhibitor, particularly a retina choroidal scar formation and contraction inhibitor in any tissue on the retina, in the retina, or in the subretinal region.
- the present invention relates to [1] (E) -4- (2- ⁇ 3-[(1H-pyrazol-1-yl) methyl] -5,5,8,8-tetramethyl-5,6,7, 8-tetrahydronaphthalen-2-yl ⁇ vinyl) benzoic acid, its ester or a salt thereof containing as an active ingredient an inhibitor of choroidal disorder, [2] (E) -4- (2- ⁇ 3- [ ((1H-pyrazol-1-yl) methyl] -5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl ⁇ vinyl) benzoic acid, its ester or a salt thereof , (E) -4- (2- ⁇ 3-[(1H-pyrazol-1-yl) methyl] -5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalene-2- Il ⁇ vinyl) benzoic acid or a salt thereof, the network context according to the
- FIG. 4 is a diagram showing the results of examining the inhibitory effect of subretinal scar formation when benzoic acid is injected in the production of a mouse subretinal scar model.
- FIG. 2A shows the result of observation under the retina 7 days after injection of macrophages and 50 ⁇ g of the present benzoic acid
- FIG. 2B shows 7 days after the injection in the case of injecting 1 ⁇ g, 5 ⁇ g, and 50 ⁇ g of macrophages and the present benzoic acid.
- the result of measuring the scar area under the retina is shown.
- “*” indicates that there is a statistically significant difference (p ⁇ 0.05).
- the inhibitor of the choroidal disorder of the present invention is not particularly limited as long as the benzoic acid represented by the following formula (I), its ester or a salt thereof is an active ingredient, but the benzoic acid or its It is preferable to use a salt as an active ingredient, and as another aspect of the present invention, a method for treating a choroidal disorder, which comprises administering the benzoic acid, an ester thereof or a salt thereof to a subject, Examples thereof include the use of the present benzoic acid, its ester or a salt thereof, and the present benzoic acid, an ester or a salt thereof for use as an inhibitor of choroidal disorder in the preparation of an inhibitor of a choroidal disorder.
- reticulochoroidal disorder refers to damage to the cells composed of photoreceptor cells, ganglion cells, retinal pigment epithelial cells and the above cells in the retina and choroid, and ultimately cell death and tissue dysfunction.
- abnormal visual functions such as visual acuity and visual field, such as the formation and contraction of reticulo-choroidal scars, diabetic retinopathy, age-related macular degeneration, retinal detachment, proliferative vitreoretinopathy
- Retinal vitreous diseases such as uveitis, eye infections, retinopathy of prematurity, neovascular macular disease, and chorioretinitis can be preferably exemplified, and formation and contraction of choroidal scars are particularly preferably exemplified be able to.
- the retina choroidal scar refers to a fibrous connective tissue formed at the damaged site on the retina, in the retina and under the retina, preferably a fiber generated at the damaged site under the retina, as the inflammation of the eye subsides or progresses.
- Sexual connective tissue which is composed mainly of retinal pigment epithelial cells, fibroblasts, glial cells, etc. and an extracellular matrix including collagen.
- the term “on the retina” refers to the surface of the retina, and “subretinal” refers to the space between the retina and the choroid, the inside of the choroid, and the subchoroid.
- reticulum scar refers to the formation of fibrous connective tissue at the lesion site on the retina, in the retina, and under the retina as the eye inflammation subsides or progresses. Refers to the contraction by attracting the tissue around the retina choroidal scar as the formed choroidal scar is healed. The formation and contraction of such a choroidal scar occurs in a series, and by suppressing the formation and contraction of the reticulochoral scar, the macular region of the reticulochoral scar and the surrounding tissue are deformed, and the choroidal function is impaired. Can be prevented.
- the benzoic acid, its ester or salt thereof, which is an active ingredient of the therapeutic agent for retina choroidal disorder of the present invention can be produced according to the method described in Patent Document 2 above, and a commercially available product is purchased. You can also.
- An example of such a commercial product is a product name: Palovarotene manufactured by Shanghai Haoyuan Chemexpress.
- the present benzoic acid, an ester thereof, or an ester thereof, which is an active ingredient of the therapeutic agent for retina choroidal disorder of the present invention is an ester that is converted to the present benzoic acid by a reaction with an enzyme or the like under physiological conditions in vivo.
- the ester is not particularly limited as long as it is an ester with a primary alcohol such as methanol, ethanol, propanol, hexanol or dodecanol; an ester with a secondary alcohol such as isopropanol, s-butanol or 1-ethylpropanol; Preferable examples include esters with tertiary alcohols such as t-butanol or 1-methyl-1-ethylpropanol; or esters with amino alcohols such as 2-aminoethanol.
- a primary alcohol such as methanol, ethanol, propanol, hexanol or dodecanol
- an ester with a secondary alcohol such as isopropanol, s-butanol or 1-ethylpropanol
- Preferable examples include esters with tertiary alcohols such as t-butanol or 1-methyl-1-ethylpropanol; or esters with amino alcohols such as 2-a
- the above ester can be produced from the benzoic acid or a synthetic intermediate thereof by a known method.
- the salt of the present benzoic acid, an ester thereof or a salt thereof, which is an active ingredient of the inhibitor of the choroidal disorder of the present invention is not particularly limited as long as it is a pharmaceutically acceptable salt.
- inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or phosphate; or acetate, trifluoroacetate, benzoate, oxalic acid Salt, malonate, succinate, maleate, fumarate, tartrate, citrate, methanesulfonate, ethanesulfonate, trifluoromethanesulfonate, benzenesulfonate, p-toluenesulfone Acid salt, organic acid salt such as glutamate or aspartate, or (2) gold such as sodium salt, potassium salt, calcium salt or magnesium salt as basic salt Salt; inorganic salts such as ammonium salts; organic amine salts such
- the inhibitor of retina choroidal disorder of the present invention is produced by mixing with an appropriate pharmacologically acceptable additive, ointment (preferably eye ointment), injection, tablet, granule, fine granule , Powder, capsule, inhalation, syrup, pill, solution, suspension, emulsion, transdermal absorption, suppository, lotion, etc., orally or parenterally (intravenous, intramuscular Administration, intraperitoneal administration, transdermal administration, transrespiratory administration, intradermal administration or subcutaneous administration).
- ointment preferably eye ointment
- injection tablet, granule, fine granule , Powder, capsule, inhalation, syrup, pill, solution, suspension, emulsion, transdermal absorption, suppository, lotion, etc.
- parenterally intravenous, intramuscular Administration, intraperitoneal administration, transdermal administration, transrespiratory administration, intradermal administration or subcutaneous administration.
- Excipients include, for example, organic excipients or inorganic excipients.
- organic excipient include sugar derivatives such as lactose, sucrose, glucose, mannitol or sorbitol; starch derivatives such as corn starch, potato starch, ⁇ -starch or dextrin; cellulose derivatives such as crystalline cellulose; gum arabic; Dextran; or pullulan and the like.
- inorganic excipients include light anhydrous silicic acid; or sulfates such as calcium sulfate.
- Lubricants include, for example, stearic acid; stearic acid metal salts such as calcium stearate or magnesium stearate; talc; colloidal silica; waxes such as beeswax or gallow; boric acid; adipic acid; sulfate such as sodium sulfate; glycol Fumaric acid; sodium benzoate; D, L-leucine; sodium lauryl sulfate; silicic acids such as anhydrous silicic acid or silicic acid hydrate; or starch derivatives in the above-mentioned excipients.
- binder examples include hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, macrogol, and compounds shown by the above-mentioned excipients.
- Disintegrants include, for example, cellulose derivatives such as low substituted hydroxypropylcellulose, carboxymethylcellulose, carboxymethylcellulose calcium or internally crosslinked carboxymethylcellulose calcium; crosslinked polyvinylpyrrolidone; or chemically modified starch such as carboxymethyl starch or sodium carboxymethyl starch Or a cellulose derivative etc. are mentioned.
- the emulsifier is, for example, colloidal clay such as bentonite or bee gum; an anionic surfactant such as sodium lauryl sulfate; a cationic surfactant such as benzalkonium chloride; or polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester Or nonionic surfactants, such as sucrose fatty acid ester, etc. are mentioned.
- Stabilizers include, for example, parahydroxybenzoates such as methylparaben or propylparaben; alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol; benzalkonium chloride; phenols such as phenol or cresol; thimerosal; acetic anhydride Or sorbic acid.
- parahydroxybenzoates such as methylparaben or propylparaben
- alcohols such as chlorobutanol, benzyl alcohol or phenylethyl alcohol
- benzalkonium chloride phenols such as phenol or cresol
- thimerosal acetic anhydride Or sorbic acid.
- sweeteners such as saccharin sodium or aspartame
- acidulants such as citric acid, malic acid or tartaric acid
- flavors such as menthol, lemon extract or orange extract.
- Diluents are compounds that are usually used as diluents, such as lactose, mannitol, glucose, sucrose, calcium sulfate, hydroxypropylcellulose, microcrystalline cellulose, water, ethanol, polyethylene glycol, propylene glycol, glycerol, Examples thereof include starch, polyvinyl pyrrolidone, and mixtures thereof.
- an ointment preferably an eye ointment
- a commonly used base such as white petrolatum or liquid paraffin.
- examples of the inhibitor of retina choroid disorder according to the present invention include eye drops, and the eye drops can be administered by eye drops.
- eye drops can be formulated in a well-known manner by appropriately adding an isotonic agent, buffer, pH adjuster, solubilizer, thickener, stabilizer, preservative (preservative), etc. as additives.
- an isotonic agent buffer, pH adjuster, solubilizer, thickener, stabilizer, preservative (preservative), etc.
- a stable eye drop can be obtained by adding a pH adjuster, a thickener, a dispersant and the like to suspend the drug.
- isotonic agent examples include glycerin, propylene glycol, sodium chloride, potassium chloride, sorbitol, mannitol and the like.
- buffer examples include phosphoric acid, phosphate, citric acid, acetic acid, and ⁇ -aminocaproic acid.
- pH adjuster examples include hydrochloric acid, citric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide, boric acid, borax, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium carbonate or sodium hydrogen carbonate. Etc.
- solubilizer examples include polysorbate 80, polyoxyethylene hydrogenated castor oil 60, macrogol 4000, and the like.
- thickener and dispersant examples include cellulose-based polymers such as hydroxypropylmethylcellulose or hydroxypropylcellulose; polyvinyl alcohol; or polyvinylpyrrolidone, and examples of the stabilizer include edetic acid or sodium edetate. Etc.
- preservatives examples include general-purpose sorbic acid, potassium sorbate, benzalkonium chloride, benzethonium chloride, methyl paraoxybenzoate, propyl paraoxybenzoate or chlorobutanol. It can also be used in combination.
- the pH of the eye drop may be within the range acceptable for ophthalmic preparations, but is preferably set to 4.0 to 8.5.
- the dosage of the inhibitor of the choroidal disorder of the present invention can be appropriately changed according to the dosage form, the severity of the patient's symptoms to be administered, age, weight, judgment of the doctor, etc. Can be administered to an adult at a dose of 0.01 to 5000 mg, preferably 0.1 to 2500 mg, more preferably 0.5 to 1000 mg per day, in one or several divided doses. In the case of eye drops, 0.000001 to 10% (W / V), preferably 0.00001 to 3% (W / V), more preferably 0.0001 to 1% (W / V).
- the active ingredient concentration can be administered once or several times a day.
- an active ingredient concentration of 0.001 to 1% (W / W) can be administered once or several times a day.
- Type I collagen (3 mg / ml: product number 637-00653; manufactured by Nitta Gelatin), 10 ⁇ MEM, restitution buffer (product number 635-00791; manufactured by Nitta Gelatin), cell suspension (1.1 ⁇ 10 7 cells / ml in MEM) and water were mixed on ice at a volume ratio of 7: 1: 1: 0.2: 1.8.
- This mixed solution (0.5 ml) was seeded on a culture dish coated with 1% BSA, and incubated at 37 ° C. for 1 hour to prepare a collagen gel.
- FIG. 1 shows that the present benzoic acid suppresses collagen gel contraction by TGF using mouse retinal pigment epithelial cells. This is because this benzoic acid contributes to collagen turnover and is effective in suppressing retina choroidal damage, and tissue remodeling after ocular tissue inflammation, bleeding, infection, surgery, trauma, etc. This indicates that it has an effect of suppressing tissue fibrosis, retina choroidal scar formation and contraction.
- a 33G needle was inserted from the flat part of the ciliary body, and 0.5 ⁇ l of 4 ⁇ 10 7 ml thioglycolate-induced peritoneal macrophages and 1 ⁇ g, 5 ⁇ g, or 50 ⁇ g of this benzoic acid were injected under the retina.
- the present benzoic acid was not injected (0 ⁇ g).
- the subretinal area was observed and the subretinal scar area was measured 7 days after the injection of the macrophages and the benzoic acid. The results are shown in FIG.
- Prescription Example 1 In 100 ml of eye drops The present benzoic acid 100 mg Sodium chloride 800mg Polysorbate 80 Appropriate amount Disodium hydrogen phosphate Appropriate amount Sodium dihydrogen phosphate Appropriate amount Sterilized purified water Appropriate amount Add the benzoic acid and the above-mentioned components to sterile purified water, and mix them well to prepare an ophthalmic solution. By changing the amount of benzoic acid etc. added, the concentration is 0.05% (W / V), 0.3% (W / V), 0.5% (W / V) or 1% (W / V). ) Eye drops.
- Ophthalmic ointment 100g In this case benzoic acid 0.3g Liquid paraffin 10.0g Appropriate amount of white petrolatum An ointment is prepared by adding this benzoic acid to uniformly melted white petrolatum and liquid paraffin, mixing them well, and then cooling them slowly. By changing the amount of benzoic acid etc. added, the concentration is 0.05% (W / W), 0.1% (W / W), 0.5% (W / W) or 1% (W / W) ) Eye ointment.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
マウス網膜色素上皮細胞を用い、Nishidaらの方法(Investigative Ophthalmology & Visual Science, 42, 1247-1253(2001))に準じて、3次元コラーゲンゲル収縮に対する被験化合物の抑制効果を評価した。マウス眼球より網膜色素上皮細胞を含む、網膜下のシート状の色素上皮細胞を採取し、初期培養した。培養した細胞を0.05%トリプシン-EDTAにより培養スライドから剥離して回収し、血清無し培地(MEM:製品番号11095;Gibco社製)で2回洗浄後、血清無し培地を加えて細胞懸濁液を作製した。タイプIコラーゲン(3mg/ml:製品番号637-00653;新田ゼラチン社製)、10×MEM、reconstitution buffer(製品番号635-00791;新田ゼラチン社製)、細胞懸濁液(1.1×107cells/ml in MEM)と水を、容量比7:1:1:0.2:1.8にて氷上で混合した。この混合液(0.5ml)を1%BSAでコートした培養ディッシュに播種し、37℃で1時間インキュベーションしてコラーゲンゲルを作製した。次いで、TGF-β2(R&D社製)1ng/ml及び本件安息香酸を0、0.01、0.1、1μM添加した血清無し培地をコラーゲンゲル上にそれぞれ0.5ml加えて37℃でインキュベートし、ゲルの直径を24時間後に測定した。コントロールとして血清無し培地のみを0.5ml加えて同様にインキュベートした。結果を図1に示す。
図1より、本件安息香酸は、マウス網膜色素上皮細胞を用いた、TGFによるコラーゲンゲル収縮を抑制することがわかる。このことは、本件安息香酸がコラーゲンのターンオーバーに寄与し、網脈絡膜障害の抑制に有効であり、眼組織での炎症、出血、感染、手術、外傷等の後に起こる組織リモデリング、つまり、網膜組織線維化、網脈絡膜瘢痕形成及び収縮を抑制する作用があるということを示している。
マウスの網膜下瘢痕モデルを作製することにより、本件安息香酸が網膜下瘢痕形成の抑制効果を有するかを調べた。マウスにおける網膜下瘢痕モデルは、Young-joonらの方法(Investigative Ophthalmology & Visual Science, 52, 6089-6095(2001))に準じて以下に示す方法で作製した。
まず、マウスC57BL/6(SLC社より購入)の眼底後ろ極部に、1箇所レーザー照射(0.05秒、200mW、532nm)を行い、ブルッフ膜を破壊した。これにより、脈絡膜からの炎症細胞浸潤を可能にすると同時に、網膜下にエアバブルを生じさせた。
図2Aに示すように、本件安息香酸を50μg注入した場合には、コントロールと比較して瘢痕の形成が抑制されていた。また、図2Bに示すように、本件安息香酸の注入量が増加するにつれて、瘢痕領域(線維化領域)が狭くなっており、本件安息香酸により網膜下瘢痕の形成及び収縮を抑制可能であることが明らかとなった。
(処方例1)点眼剤
100ml中
本件安息香酸 100mg
塩化ナトリウム 800mg
ポリソルベート80 適量
リン酸水素二ナトリウム 適量
リン酸二水素ナトリウム 適量
滅菌精製水 適量
滅菌精製水に本件安息香酸及びそれ以外の上記成分を加え、これらを十分に混合して点眼液を調製する。本件安息香酸等の添加量を変えることにより、濃度が0.05%(W/V)、0.3%(W/V)、0.5%(W/V)又は1%(W/V)の点眼剤を調製できる。
100g中
本件安息香酸 0.3g
流動パラフィン 10.0g
白色ワセリン 適量
均一に溶融した白色ワセリン及び流動パラフィンに、本件安息香酸を加え、これらを十分に混合して後に徐々に冷却することで眼軟膏を調製する。本件安息香酸等の添加量を変えることにより、濃度が0.05%(W/W)、0.1%(W/W)、0.5%(W/W)又は1%(W/W)の眼軟膏を調製できる。
100mg中
本件安息香酸 1mg
乳糖 66.4mg
トウモロコシデンプン 20mg
カルボキシメチルセルロースカルシウム 6mg
ヒドロキシプロピルセルロース 6mg
ステアリン酸マグネシウム 0.6mg
本件安息香酸、トウモロコシデンプン及び乳糖を混合機中で混合し、その混合物にカルボキシメチルセルロースカルシウム及びヒドロキシプロピルセルロースを加えて造粒し、得られた顆粒を乾燥後整粒し、その整粒顆粒にステアリン酸マグネシウムを加えて混合し、打錠機で打錠する。また、本件安息香酸等の添加量を変えることにより、100mg中の含有量が0.1mg、10mg又は50mgの錠剤を調製できる。
Claims (5)
- (E)-4-(2-{3-[(1H-ピラゾール-1-イル)メチル]-5,5,8,8-テトラメチル-5,6,7,8-テトラヒドロナフタレン-2-イル}ビニル)安息香酸、そのエステル又はそれらの塩を有効成分として含有する網脈絡膜障害の抑制剤。
- (E)-4-(2-{3-[(1H-ピラゾール-1-イル)メチル]-5,5,8,8-テトラメチル-5,6,7,8-テトラヒドロナフタレン-2-イル}ビニル)安息香酸、そのエステル又はそれらの塩が、(E)-4-(2-{3-[(1H-ピラゾール-1-イル)メチル]-5,5,8,8-テトラメチル-5,6,7,8-テトラヒドロナフタレン-2-イル}ビニル)安息香酸又はその塩である、請求項1記載の網脈絡膜障害の抑制剤。
- 網脈絡膜障害が、網膜上、網膜内、又は網膜下のいずれかの組織における網脈絡膜瘢痕の形成及び収縮である、請求項1又は2記載の網脈絡膜障害の抑制剤。
- 投与形態が点眼投与又は経口投与である、請求項1~3のいずれか記載の網脈絡膜障害の抑制剤。
- 剤型が、点眼剤、眼軟膏、注射剤、錠剤、顆粒剤、細粒剤、散剤又はカプセル剤である、請求項1~4のいずれか記載の網脈絡膜障害の抑制剤。
Priority Applications (24)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES14800477.3T ES2694831T3 (es) | 2013-05-22 | 2014-05-21 | Inhibidor para trastornos retinocoroideos |
JP2015518078A JP6407145B2 (ja) | 2013-05-22 | 2014-05-21 | 網脈絡膜障害の抑制剤 |
MX2015016083A MX362239B (es) | 2013-05-22 | 2014-05-21 | Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales. |
BR112015029114-7A BR112015029114B1 (pt) | 2013-05-22 | 2014-05-21 | composição |
PL14800477T PL3000466T3 (pl) | 2013-05-22 | 2014-05-21 | Inhibitor dla zaburzeń siatkówkowo-naczyniówkowych |
EP14800477.3A EP3000466B1 (en) | 2013-05-22 | 2014-05-21 | Inhibitor for retinochoroidal disorders |
DK14800477.3T DK3000466T3 (en) | 2013-05-22 | 2014-05-21 | INHIBITOR FOR RETINOCHOROIDAL DISEASES |
KR1020157035402A KR102303316B1 (ko) | 2013-05-22 | 2014-05-21 | 망막 맥락막 장해의 억제제 |
EP18183955.6A EP3446690A1 (en) | 2013-05-22 | 2014-05-21 | Inhibitor for retinochoroidal disorders |
CA2913005A CA2913005C (en) | 2013-05-22 | 2014-05-21 | Inhibitor for retinochoroidal disorders |
CN201480041392.4A CN105377258B (zh) | 2013-05-22 | 2014-05-21 | 视网膜脉络膜病症的抑制剂 |
US14/892,536 US10702502B2 (en) | 2013-05-22 | 2014-05-21 | Inhibitor for retinochoroidal disorders |
LTEP14800477.3T LT3000466T (lt) | 2013-05-22 | 2014-05-21 | Retinochorioidinių sutrikimų slopiklis |
RS20181364A RS58045B1 (sr) | 2013-05-22 | 2014-05-21 | Inhibitor za retinohoroidalne poremećaje |
SI201430951T SI3000466T1 (sl) | 2013-05-22 | 2014-05-21 | Inhibitor za retinohoroidalne motnje |
AU2014269762A AU2014269762B2 (en) | 2013-05-22 | 2014-05-21 | Inhibitor for retinochoroidal disorders |
RU2015154741A RU2672057C2 (ru) | 2013-05-22 | 2014-05-21 | Ингибитор хориоретинальных нарушений |
NZ715245A NZ715245B2 (en) | 2013-05-22 | 2014-05-21 | Inhibitor for retinochoroidal disorders |
ZA2015/08940A ZA201508940B (en) | 2013-05-22 | 2015-12-08 | Inhibitor for retinochoroidal disorders |
HK16110132.0A HK1221909A1 (zh) | 2013-05-22 | 2016-08-25 | 視網膜脈絡膜病症的抑制劑 |
HRP20181876TT HRP20181876T1 (hr) | 2013-05-22 | 2018-11-08 | Inhibitor za retinokoroidalne poremećaje |
CY181101204T CY1121036T1 (el) | 2013-05-22 | 2018-11-14 | Παρεμποδιστης για αμφιβληστροειδοχοριοειδικες διαταραχες |
US16/893,120 US11730718B2 (en) | 2013-05-22 | 2020-06-04 | Inhibitor for retinochoroidal disorders |
US18/219,765 US20240180873A1 (en) | 2013-05-22 | 2023-07-10 | Inhibitor for retinochoroidal disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-107706 | 2013-05-22 | ||
JP2013107706 | 2013-05-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/892,536 A-371-Of-International US10702502B2 (en) | 2013-05-22 | 2014-05-21 | Inhibitor for retinochoroidal disorders |
US16/893,120 Continuation US11730718B2 (en) | 2013-05-22 | 2020-06-04 | Inhibitor for retinochoroidal disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014188716A1 true WO2014188716A1 (ja) | 2014-11-27 |
Family
ID=51933283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/002667 WO2014188716A1 (ja) | 2013-05-22 | 2014-05-21 | 網脈絡膜障害の抑制剤 |
Country Status (22)
Country | Link |
---|---|
US (3) | US10702502B2 (ja) |
EP (2) | EP3000466B1 (ja) |
JP (2) | JP6407145B2 (ja) |
KR (1) | KR102303316B1 (ja) |
CN (1) | CN105377258B (ja) |
AU (1) | AU2014269762B2 (ja) |
BR (1) | BR112015029114B1 (ja) |
CA (1) | CA2913005C (ja) |
CY (1) | CY1121036T1 (ja) |
DK (1) | DK3000466T3 (ja) |
ES (1) | ES2694831T3 (ja) |
HK (1) | HK1221909A1 (ja) |
HR (1) | HRP20181876T1 (ja) |
LT (1) | LT3000466T (ja) |
MX (1) | MX362239B (ja) |
PL (1) | PL3000466T3 (ja) |
PT (1) | PT3000466T (ja) |
RS (1) | RS58045B1 (ja) |
RU (1) | RU2672057C2 (ja) |
SI (1) | SI3000466T1 (ja) |
WO (1) | WO2014188716A1 (ja) |
ZA (1) | ZA201508940B (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9492431B2 (en) | 2012-11-08 | 2016-11-15 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
JP2018115221A (ja) * | 2013-05-22 | 2018-07-26 | 国立大学法人山口大学 | 網脈絡膜障害の抑制剤 |
JP2019534336A (ja) * | 2016-11-16 | 2019-11-28 | クレメンティア ファーマシューティカルズ インコーポレイテッド | 多発性骨軟骨腫(mo)を処置するための方法 |
US11622959B2 (en) | 2016-06-08 | 2023-04-11 | Clementia Pharmaceuticals Inc. | Methods for treating heterotopic ossification |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012030919A2 (en) | 2010-09-01 | 2012-03-08 | Thomas Jefferson University | Composition and method for muscle repair and regeneration |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11503998A (ja) * | 1995-02-01 | 1999-04-06 | ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | レチノイン酸受容体アゴニストによる網膜色素上皮の増殖の阻止方法 |
WO2002028810A2 (en) | 2000-10-02 | 2002-04-11 | F. Hoffmann-La Roche Ag | Retinoids for the treatment of emphysema |
WO2007037188A1 (ja) | 2005-09-27 | 2007-04-05 | Sapporo Medical University | 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬 |
WO2008057930A2 (en) | 2006-11-02 | 2008-05-15 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with retinoic acid receptor agonists |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT678086E (pt) * | 1993-01-11 | 2000-05-31 | Ligand Pharm Inc | Compostos com selectividade para receptores de retinoides x |
US5624957A (en) | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
US7514074B2 (en) | 1997-07-14 | 2009-04-07 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
US6204288B1 (en) | 1999-03-08 | 2001-03-20 | The University Of Mississippi | 1,2-dithiolane derivatives |
US20030114482A1 (en) | 1999-12-15 | 2003-06-19 | Maurizio Pacifici | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
US6313168B1 (en) | 1999-12-15 | 2001-11-06 | Allergan Sales, Inc. | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
AU784377B2 (en) | 2000-03-14 | 2006-03-23 | Arthur V. Sampaio | Compositions and methods for affecting osteogenesis |
RU2299877C2 (ru) | 2001-09-18 | 2007-05-27 | Ф.Хоффманн-Ля Рош Аг | Производные алкилмочевины, обладающие свойствами ретиноидных агонистов (i), фармацевтическая композиция и лекарственное средство |
PL209697B1 (pl) | 2001-09-18 | 2011-10-31 | Hoffmann La Roche | Pochodne mocznika, środek farmaceutyczny i zastosowanie pochodnych mocznika |
AUPR892501A0 (en) | 2001-11-16 | 2001-12-13 | Peter Maccallum Cancer Institute, The | Method of enhancing self renewal of stem cells and uses thereof |
US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
JP2005206544A (ja) | 2004-01-23 | 2005-08-04 | Yasuyoshi Uchida | 筋肉再生剤 |
AU2005240078A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
EA200701998A1 (ru) * | 2005-03-17 | 2008-02-28 | Элан Фарма Интернэшнл Лтд. | Композиции для инъекций наночастиц иммунодепрессивных соединений |
US7345931B2 (en) | 2005-08-01 | 2008-03-18 | Infineon Technologies Ag | Maintaining internal voltages of an integrated circuit in response to a clocked standby mode |
KR20070037188A (ko) | 2005-09-30 | 2007-04-04 | 현대자동차주식회사 | 자동 변속기에서 유량 제어구조 |
AU2007233868A1 (en) * | 2006-03-31 | 2007-10-11 | F. Hoffmann-La Roche Ag | Process for preparing retinoid compounds |
JP2009537540A (ja) | 2006-05-16 | 2009-10-29 | ビテ ファーマシューティカルズ, インコーポレイテッド | 化学療法および/または放射線療法の副作用を処置するためのrarアンタゴニストまたはrarインバースアゴニストの使用 |
JP5732182B2 (ja) | 2006-10-27 | 2015-06-10 | エルパス・インコーポレイテッドLpath, Inc. | 眼疾患と症状を処置するための組成物および方法 |
US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
JP2009235031A (ja) | 2008-03-28 | 2009-10-15 | Nano Egg:Kk | 角膜組織の再生促進剤 |
WO2010071583A1 (en) | 2008-12-18 | 2010-06-24 | Astrazeneca Ab | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient |
WO2010088735A1 (en) | 2009-02-05 | 2010-08-12 | Regenertech Pty Ltd | Method of producing progenitor cells from differentiated cells |
WO2012030919A2 (en) | 2010-09-01 | 2012-03-08 | Thomas Jefferson University | Composition and method for muscle repair and regeneration |
WO2012047674A2 (en) | 2010-09-27 | 2012-04-12 | Microdose Therapeutx, Inc. | Methods and compositions for disease treatment using inhalation |
WO2012125724A1 (en) | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of proliferative disorders |
WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
US8772273B2 (en) | 2011-10-04 | 2014-07-08 | Quretino Therapeutics, Inc. | Formulations and uses of retinoic acid receptor selective agonists |
KR102173932B1 (ko) | 2012-11-08 | 2020-11-04 | 고쿠리츠다이가쿠호우진 야마구치 다이가쿠 | 각결막 장해의 치료제 |
MX362239B (es) * | 2013-05-22 | 2019-01-09 | Univ Yamaguchi | Uso del a´cido (e)-4-(2-{3-[ (1h-pirazol-1-il)metil]-5,5,8,8- tetrametil-5,6,7,8-tetrahidronaftalen-2-il}vinil)benzoico en el tratamiento de trastornos retinocoroidales. |
-
2014
- 2014-05-21 MX MX2015016083A patent/MX362239B/es active IP Right Grant
- 2014-05-21 EP EP14800477.3A patent/EP3000466B1/en active Active
- 2014-05-21 AU AU2014269762A patent/AU2014269762B2/en active Active
- 2014-05-21 JP JP2015518078A patent/JP6407145B2/ja active Active
- 2014-05-21 RS RS20181364A patent/RS58045B1/sr unknown
- 2014-05-21 WO PCT/JP2014/002667 patent/WO2014188716A1/ja active Application Filing
- 2014-05-21 PT PT14800477T patent/PT3000466T/pt unknown
- 2014-05-21 ES ES14800477.3T patent/ES2694831T3/es active Active
- 2014-05-21 PL PL14800477T patent/PL3000466T3/pl unknown
- 2014-05-21 KR KR1020157035402A patent/KR102303316B1/ko active IP Right Grant
- 2014-05-21 US US14/892,536 patent/US10702502B2/en active Active
- 2014-05-21 LT LTEP14800477.3T patent/LT3000466T/lt unknown
- 2014-05-21 SI SI201430951T patent/SI3000466T1/sl unknown
- 2014-05-21 BR BR112015029114-7A patent/BR112015029114B1/pt active IP Right Grant
- 2014-05-21 RU RU2015154741A patent/RU2672057C2/ru active
- 2014-05-21 CN CN201480041392.4A patent/CN105377258B/zh active Active
- 2014-05-21 EP EP18183955.6A patent/EP3446690A1/en active Pending
- 2014-05-21 DK DK14800477.3T patent/DK3000466T3/en active
- 2014-05-21 CA CA2913005A patent/CA2913005C/en active Active
-
2015
- 2015-12-08 ZA ZA2015/08940A patent/ZA201508940B/en unknown
-
2016
- 2016-08-25 HK HK16110132.0A patent/HK1221909A1/zh unknown
-
2018
- 2018-05-07 JP JP2018089396A patent/JP6749962B2/ja active Active
- 2018-11-08 HR HRP20181876TT patent/HRP20181876T1/hr unknown
- 2018-11-14 CY CY181101204T patent/CY1121036T1/el unknown
-
2020
- 2020-06-04 US US16/893,120 patent/US11730718B2/en active Active
-
2023
- 2023-07-10 US US18/219,765 patent/US20240180873A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11503998A (ja) * | 1995-02-01 | 1999-04-06 | ザ ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン | レチノイン酸受容体アゴニストによる網膜色素上皮の増殖の阻止方法 |
WO2002028810A2 (en) | 2000-10-02 | 2002-04-11 | F. Hoffmann-La Roche Ag | Retinoids for the treatment of emphysema |
WO2007037188A1 (ja) | 2005-09-27 | 2007-04-05 | Sapporo Medical University | 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬 |
WO2008057930A2 (en) | 2006-11-02 | 2008-05-15 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with retinoic acid receptor agonists |
Non-Patent Citations (3)
Title |
---|
JUNKO UE ET AL.: "38. Efficacy of retinoic acid receptor-specific agonist on choroidal neovascularization in mice", RESEARCH ON RETINOCHOROIDAL AND OPTIC ATROPHY HEISEI 15 NENDO SOKATSU ., 31 March 2004 (2004-03-31), pages 209 - 211, XP008182068 * |
NISHIDA ET AL., INVESTIGATIVE OPHTHALMOLOGY &VISUAL SCIENCE, vol. 42, 2001, pages 1247 - 1253 |
YOUNG-J OON ET AL., INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 52, 2001, pages 6089 - 6095 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9492431B2 (en) | 2012-11-08 | 2016-11-15 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US9750721B2 (en) | 2012-11-08 | 2017-09-05 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US10016395B2 (en) | 2012-11-08 | 2018-07-10 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US10537556B2 (en) | 2012-11-08 | 2020-01-21 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
US11471440B2 (en) | 2012-11-08 | 2022-10-18 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
JP2018115221A (ja) * | 2013-05-22 | 2018-07-26 | 国立大学法人山口大学 | 網脈絡膜障害の抑制剤 |
US11622959B2 (en) | 2016-06-08 | 2023-04-11 | Clementia Pharmaceuticals Inc. | Methods for treating heterotopic ossification |
JP2019534336A (ja) * | 2016-11-16 | 2019-11-28 | クレメンティア ファーマシューティカルズ インコーポレイテッド | 多発性骨軟骨腫(mo)を処置するための方法 |
JP7018957B2 (ja) | 2016-11-16 | 2022-02-14 | クレメンティア ファーマシューティカルズ インコーポレイテッド | 多発性骨軟骨腫(mo)を処置するための方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11730718B2 (en) | Inhibitor for retinochoroidal disorders | |
JP2008308489A (ja) | ロピニロール又はその塩を有効成分として含有する後眼部疾患の予防又は治療剤 | |
JP6462836B2 (ja) | 角結膜障害の治療剤 | |
WO2011149012A1 (ja) | イソキノリンスルホニル誘導体を有効成分として含有する網脈絡膜変性疾患の予防または治療剤、網脈絡膜変性疾患の予防または治療方法、イソキノリンスルホニル誘導体またはその医薬的に許容される塩、ならびにその使用 | |
WO2005007161A1 (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
EP4052694A1 (en) | Eye drop composition for preventing or treating eye disease | |
JP2005047909A (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
CA3088185C (en) | Suspension compositions of multi-target inhibitors | |
KR20110084514A (ko) | 피리딘-3-카르발데히드 o-(피페리딘-1-일-프로필)-옥심 유도체를 유효 성분으로서 함유하는 망맥락막 변성 질환의 치료제 | |
KR20150051493A (ko) | 이매티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관신생 관련 질환의 예방 또는 치료용 약학적 조성물 | |
NZ715245B2 (en) | Inhibitor for retinochoroidal disorders | |
JP2014193854A (ja) | テトラヒドロピラニルアミノシクロペンチルカルボニルテトラヒドロピリドピリジン誘導体を有効成分として含有する後眼部疾患の予防または治療剤 | |
KR101869741B1 (ko) | 마시티닙 또는 이의 약학적으로 허용되는 염을 유효성분으로 포함하는 혈관 투과성 관련 질환의 예방 또는 치료용 약학적 조성물 | |
WO2013180209A1 (ja) | ペプチド誘導体を含有する緑内障の治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14800477 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2913005 Country of ref document: CA Ref document number: 2015518078 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14892536 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/016083 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 20157035402 Country of ref document: KR Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015029114 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2015154741 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014800477 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014269762 Country of ref document: AU Date of ref document: 20140521 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112015029114 Country of ref document: BR Kind code of ref document: A2 Effective date: 20151119 |